“Long COVID Treatment: Evidence-Based Options and What Actually Helps”

Why Long COVID Treatment Is So Complicated

Long COVID is not one disease. It is a collection of overlapping syndromes, and what drives symptoms in one person may be completely different from what drives them in another. Some patients have viral persistence, meaning fragments of SARS-CoV-2 are still detectable months later. Others have autoimmune dysregulation, microbiome disruption, reactivated latent viruses like Epstein-Barr, or autonomic nervous system dysfunction. Many have a combination [1].

This is why treatments that help some people do nothing for others. It also explains why clinical trials have been difficult to run. The NIH’s RECOVER initiative, the largest long COVID research program ever funded, has faced criticism for being slow to produce actionable treatment data. As of 2025, no drug is formally approved specifically for Long COVID, though several are used off-label with good rationale [2].

The practical approach that most Long COVID clinics now take is to identify which subtype or symptom cluster a patient fits, then target treatment accordingly. That framework guides what follows here.

Medications With Evidence Behind Them

Low-Dose Naltrexone (LDN)

Naltrexone at standard doses (50mg) blocks opioid receptors to treat addiction. At low doses, typically 1.5 to 4.5mg per day, it has a completely different mechanism. LDN appears to modulate microglial activation, reduce neuroinflammation, and normalize immune function. For Long COVID patients with fatigue, pain, and brain fog, a number of small trials and large patient surveys show meaningful benefit [3].

A 2023 survey of over 1,000 Long COVID patients found LDN was one of the most consistently helpful medications reported, with around 74% of users noting some improvement. It is well-tolerated, inexpensive, and available through compounding pharmacies. The main downside is that clinical trial data is still limited compared to the volume of patient-reported benefit.

Antihistamines

There is a significant subset of Long COVID patients who have elevated mast cell activity, sometimes meeting criteria for mast cell activation syndrome (MCAS). Mast cells release histamine and other mediators that can cause widespread symptoms including fatigue, brain fog, flushing, GI distress, and palpitations. Combining an H1 blocker (like fexofenadine or cetirizine) with an H2 blocker (like famotidine) has helped many patients in this group substantially [4].

Famotidine specifically has received attention beyond just histamine blockade. It appears to have anti-viral properties and has been studied as a standalone treatment for COVID-19 and Long COVID symptoms at doses of 80 to 160mg per day. A small randomized trial showed improvement in multiple Long COVID symptom domains [5].

SSRIs and SNRIs

Antidepressants sound like an odd choice for what many patients correctly identify as a physical illness, but the rationale here is biological, not psychiatric. SSRIs inhibit platelet aggregation, which may address the microclotting that some researchers believe contributes to Long COVID. Fluvoxamine also has sigma-1 receptor activity that may reduce inflammation. The TOGETHER trial found fluvoxamine reduced COVID-19 severity, and similar mechanisms may apply in the chronic phase [6].

For patients whose Long COVID features include POTS (postural orthostatic tachycardia syndrome), low-dose SSRIs can help regulate autonomic function. They are not appropriate for everyone, but for certain presentations they represent a reasonable option.

Anticoagulants and Platelet Inhibitors

Microclot theory, developed primarily by South African researchers Resia Pretorius and Douglas Kell, proposes that SARS-CoV-2 triggers the formation of tiny fibrin clots resistant to normal breakdown. These microclots may impair oxygen delivery at the capillary level, explaining symptoms like fatigue and breathlessness even when standard lung tests look normal [7].

Some clinicians are trialing low-dose anticoagulants or antiplatelet regimens based on this hypothesis. Early case series from South Africa showed promising results with triple therapy including aspirin, clopidogrel, and apixaban. This approach carries bleeding risk and is not standard care, but the mechanistic basis is solid enough that several trials are underway.

Hyperbaric Oxygen Therapy

Among all the non-drug interventions studied, HBOT has the strongest clinical trial data. A randomized, double-blind, sham-controlled trial from Israel published in Nature Communications in 2022 enrolled 73 Long COVID patients and found that 40 sessions of HBOT at 2 atmospheres with 100% oxygen produced significant improvements in cognitive function, energy, sleep, pain, and psychiatric symptoms compared to sham treatment [8].

The proposed mechanisms are multiple. Hyperbaric oxygen promotes neuroplasticity and angiogenesis. It reduces neuroinflammation. It enhances mitochondrial function. It may help clear microclots. For a condition with so many potential drivers, an intervention that addresses several simultaneously has obvious appeal.

The practical challenge is cost and access. A full protocol typically involves 40 to 60 sessions of 60 to 90 minutes each. Depending on location, this can run $10,000 to $25,000 out of pocket. Not all HBOT facilities offer the specific protocols used in trials. That said, for patients with significant cognitive or functional impairment, the trial data is strong enough that it warrants serious consideration.

NAD+ Therapy

NAD+ (nicotinamide adenine dinucleotide) is central to mitochondrial energy production and cellular repair. SARS-CoV-2 infection appears to deplete NAD+ through multiple mechanisms, including activation of PARP enzymes and CD38, both of which consume NAD+ in large quantities [9]. The resulting energy deficit at the cellular level may explain the profound fatigue that defines many Long COVID cases.

IV NAD+ delivers the molecule directly into circulation, bypassing digestive conversion and achieving much higher plasma levels than oral precursors. Clinically, many Long COVID patients report substantial energy improvements with IV NAD+ protocols, typically 3 to 10 sessions of 500 to 1000mg delivered slowly over several hours. Oral precursors like NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are less potent but offer a maintenance option.

Clinical trial data on NAD+ specifically for Long COVID is still emerging. But the mechanistic case is strong, and the safety profile is excellent. Most regenerative clinics offering Long COVID protocols include NAD+ IV as a core component.

Peptide Therapies

Peptide therapies are gaining traction in Long COVID treatment, particularly for immune dysregulation and tissue repair. Several peptides have specific relevance here.

BPC-157 (Body Protection Compound 157) has extensive animal data showing anti-inflammatory effects, gut mucosal healing, and neuroprotective properties. Given that Long COVID frequently involves gut dysbiosis and neurological symptoms, BPC-157 is being used by integrative clinicians. Human trial data is limited but the safety record is favorable [10].

Thymosin alpha-1 (Thymalfasin) is a thymic peptide that modulates immune function, particularly T-cell activity. It is approved in several countries for hepatitis and is being studied for Long COVID given that immune exhaustion and dysregulation are well-documented features of the condition. Some clinics are using it as part of immune reconditioning protocols.

Selank and Semax, nootropic peptides developed in Russia, have shown anxiolytic, anti-inflammatory, and cognitive-enhancing properties in animal and some human studies. They are being used off-label for the neurological and psychiatric symptoms of Long COVID.

Pacing and Post-Exertional Malaise Management

For patients whose Long COVID resembles ME/CFS, pacing is arguably the most important intervention available, and the most commonly given wrong advice is the opposite: graded exercise therapy (GET). Multiple studies have now shown that GET worsens outcomes in ME/CFS and in Long COVID patients with post-exertional malaise (PEM). PEM means that physical or cognitive exertion causes a disproportionate crash that can last days [11].

Heart rate monitoring is a practical tool for staying within aerobic limits. Many patients use a threshold of 60% of their heart rate reserve or subtract 15 from their anaerobic threshold. Staying below that limit during all activity, including walking and cognitive work, prevents crashes and allows gradual recovery.

This is not rest forever. It is structured activity management that gives the nervous system a chance to stabilize. Over months, patients who pace well often find their envelope expanding.

Gut Health and Microbiome Interventions

The gut-immune connection in Long COVID is well-documented. Studies using gut microbiome sequencing show that Long COVID patients have distinct dysbiosis patterns compared to people who recovered fully, with depletion of beneficial species like Faecalibacterium prausnitzii and Bifidobacterium [12]. Gut permeability appears elevated, allowing bacterial products to enter circulation and drive systemic inflammation.

Targeted probiotic interventions, particularly those including Lactobacillus rhamnosus and specific Bifidobacterium strains, have shown promise in reducing Long COVID symptom burden in early trials. Dietary approaches supporting microbiome diversity, reducing processed food, and increasing fermented food intake are being studied as complementary approaches.

Emerging Interventions Under Investigation

Several other treatments are in earlier stages of investigation. Baricitinib, a JAK inhibitor approved for rheumatoid arthritis, is being trialed based on its ability to reduce cytokine signaling. Metformin showed a 40% reduction in Long COVID incidence when used during acute infection in a trial published in The Lancet Infectious Diseases in 2023 [13], raising questions about its role in established Long COVID. Ozone therapy is used in some integrative clinics for its proposed effects on oxygen delivery and viral load reduction, though clinical trial data remains limited.

Stellate ganglion blocks, an anesthetic procedure targeting the sympathetic nervous system, are being studied for Long COVID patients with POTS and hyperadrenergic presentations. Early results from small case series are promising, particularly for autonomic symptoms and brain fog.

Building a Treatment Plan

The most effective approach to Long COVID treatment is systematic. Start with symptom clustering: which systems are most affected? Cardiovascular, neurological, metabolic, immunological, or some combination? This guides what to prioritize first.

Most Long COVID specialists recommend addressing foundational issues first: sleep quality, orthostatic intolerance (if present), and pacing to prevent PEM crashes. On top of that foundation, targeted interventions can be layered based on dominant symptom patterns.

Working with a physician who understands Long COVID and is willing to consider off-label options is significantly better than waiting for a single approved treatment that may not exist for years. The field is moving fast. What was considered fringe in 2021 is now discussed in mainstream journals, and the treatment options available today are meaningfully better than they were even two years ago.

Related Reading

• Long COVID Symptoms: The Complete Guide to Post-COVID Syndrome
• Post-COVID Fatigue: Why It Happens and How to Recover
• Long COVID Recovery: Timeline, Strategies, and When to Seek Help
• Long COVID Brain Fog Treatment
• Hyperbaric Oxygen Therapy: Benefits, Risks, and What to Expect
• NAD+ IV Therapy: What It Does and Who It Helps
• MCAS Treatment: Managing Mast Cell Activation Syndrome

References

1. Davis HE, McCorkell L, Vogel JM, Topol EJ. “Long COVID: major findings, mechanisms and recommendations.” Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
2. Kedor C, Freitag H, Meyer-Arndt L, et al. “A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with its clinical course.” Lancet EClinicalMedicine. 2022;51:101549. doi:10.1016/j.eclinm.2022.101549
3. Younger J, Parkitny L, McLain D. “The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.” Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2
4. Afrin LB, Weinstock LB, Molderings GJ. “COVID-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome.” Int J Infect Dis. 2020;100:327-332. doi:10.1016/j.ijid.2020.09.016
5. Janowitz T, Gablenz E, Pattinson D, et al. “Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients.” Gut. 2020;69(9):1592-1597. doi:10.1136/gutjnl-2020-321852
6. Lenze EJ, Mattar C, Zorumski CF, et al. “Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19.” JAMA. 2020;324(22):2292-2300. doi:10.1001/jama.2020.22760
7. Pretorius E, Venter C, Laubscher GJ, et al. “Prevalence of readily detected amyloid blood clots in unvaccinated, vaccinated and COVID-19 patients.” Cardiovasc Diabetol. 2021;20(1):172. doi:10.1186/s12933-021-01359-7
8. Efrati S, Ben-Jacob E, Reshef A, et al. “Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial.” Nat Commun. 2022;13(1):6940. doi:10.1038/s41467-022-34638-y
9. Minhas PS, Liu L, Moon PK, et al. “Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation.” Nat Immunol. 2019;20(1):50-63. doi:10.1038/s41590-018-0255-3
10. Sikiric P, Seiwerth S, Rucman R, et al. “Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.” Curr Med Chem. 2012;19(1):126-132. doi:10.2174/092986712803414004
11. Bateman L, Bested AC, Bonilla H, et al. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clin Proc. 2021;96(11):2861-2878. doi:10.1016/j.mayocp.2021.07.004
12. Liu Q, Mak JWY, Su Q, et al. “Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome.” Gut. 2022;71(3):544-552. doi:10.1136/gutjnl-2021-325989
13. Bramante CT, Buse JB, Liebovitz DM, et al. “Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.” Lancet Infect Dis. 2023;23(10):1119-1129. doi:10.1016/S1473-3099(23)00299-2